Skip to main content

The future of the 340B program: 2023 key decisions

By Foley and Lardner LLP  
   March 30, 2023

Critical decisions are pending before courts and legislators in 2023 that promise to shape the future of the 340B Drug Pricing Program (340B Program), which provides discounts on outpatient drugs for certain health care providers, referred to as covered entities. The resolution of these issues will have an enormous financial impact on the health care industry, including pharmaceutical manufacturers, 340B hospitals, and federal grantees.

Full story

Get the latest on healthcare leadership in your inbox.